<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Gianluca Gaïdano, Valeria Spina et al.|Haematologica|2019Cited by 137
ABCL-1224: Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)Rakhee Vaidya, David Andorsky, Farrukh T. Awan et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1